Table of Contents Author Guidelines Submit a Manuscript
International Journal of Otolaryngology
Volume 2009 (2009), Article ID 848695, 10 pages
http://dx.doi.org/10.1155/2009/848695
Research Article

Aberrant Methylation Inactivates Transforming Growth Factor Receptor I in Head and Neck Squamous Cell Carcinoma

1Department of Interdisciplinary Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA
2Department of Pathology, LSU Health Sciences Center, New Orleans, LA 70112, USA
3Department of Pharmacology, University of Puerto Rico School of Medicine, San Juan, PR 00936, USA
4Pathology and Laboratory Medicine, James A. Haley Veterans' Affairs Medical Center, Tampa, FL 33612, USA
5Department of Otolaryngology, University of Puerto Rico School of Medicine, San Juan, PR 00936, USA

Received 10 December 2008; Accepted 27 March 2009

Academic Editor: Alfio Ferlito

Copyright © 2009 Teresita Muñoz-Antonia et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. N. Myers, J. Y. Suen, J. Myers, and E. Hanna, Cancer of the Head and Neck, W. B. Saunders, Philadelphia, Pa, USA, 4th edition, 2003.
  2. American Cancer Society, Cancer Facts and Figures 2007, American Cancer Society, Atlanta, Ga, USA, 2007.
  3. S. G. Patel and J. P. Shah, “TNM staging of cancers of the head and neck: striving for uniformity among diversity,” CA: A Cancer Journal for Clinicians, vol. 55, no. 4, pp. 242–258, 2005. View at Publisher · View at Google Scholar
  4. A. Báez, J. I. Almodóvar, A. Cantor et al., “High frequency of HPV16-associated head and neck squamous cell carcinoma in the Puerto Rican population,” Head and Neck, vol. 26, no. 9, pp. 778–784, 2004. View at Publisher · View at Google Scholar
  5. A. R. Kreimer, G. M. Clifford, P. Boyle, and S. Franceschi, “Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systemic review,” Cancer Epidemiology Biomarkers and Prevention, vol. 14, no. 2, pp. 467–475, 2005. View at Publisher · View at Google Scholar
  6. M. Pring, S. Prime, E. K. Parkinson, and I. Paterson, “Dysregulated TGF-β1-induced Smad signalling occurs as a result of defects in multiple components of the TGF-β signalling pathway in human head and neck carcinoma cell lines,” International Journal of Oncology, vol. 28, no. 5, pp. 1279–1285, 2006. View at Google Scholar
  7. S. S. Prime, M. Davies, M. Pring, and I. C. Paterson, “The role of TGF-β in epithelial malignancy and its relevance to the pathogenesis of oral cancer (part II),” Critical Reviews in Oral Biology and Medicine, vol. 15, no. 6, pp. 337–347, 2004. View at Publisher · View at Google Scholar
  8. J. Massagué, “TGF-β signal transduction,” Annual Review of Biochemistry, vol. 67, pp. 753–791, 1998. View at Publisher · View at Google Scholar
  9. A. J. Galliher, J. R. Neil, and W. P. Schiemann, “Role of transforming growth factore-β in cancer progression,” Future Oncology, vol. 2, no. 6, pp. 743–763, 2006. View at Publisher · View at Google Scholar
  10. R. Derynck and Y. E. Zhang, “Smad-dependent and Smad-independent pathways in TGF-β family signalling,” Nature, vol. 425, no. 6958, pp. 577–584, 2003. View at Publisher · View at Google Scholar
  11. P. A. Jones and S. B. Baylin, “The epigenomics of cancer,” Cell, vol. 128, no. 4, pp. 683–692, 2007. View at Publisher · View at Google Scholar
  12. M. Esteller, P. G. Corn, S. B. Baylin, and J. G. Herman, “A gene hypermethylation profile of human cancer,” Cancer Research, vol. 61, no. 8, pp. 3225–3229, 2001. View at Google Scholar
  13. R. Parsons, L. L. Myeroff, B. Liu et al., “Microsatellite instability and mutations of the transforming growth factor ß type II receptor gene in colorectal cancer,” Cancer Research, vol. 55, no. 23, pp. 5548–5550, 1995. View at Google Scholar
  14. L. L. Myeroff, R. Parsons, S. J. Kim et al., “A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability,” Cancer Research, vol. 55, no. 23, pp. 5545–5547, 1995. View at Google Scholar
  15. D. Wang, H. Song, J. A. Evans, J. C. Lang, D. E. Schuller, and C. M. Weghorst, “Mutation and downregulation of the transforming growth factor beta type II receptor gene in primary squamous cell carcinomas of the head and neck,” Carcinogenesis, vol. 18, no. 11, pp. 2285–2290, 1997. View at Publisher · View at Google Scholar
  16. E. R. Seijo, H. Song, M. A. Lynch et al., “Identification of genetic alterations in the TGFß type II receptor gene promoter,” Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 483, no. 1-2, pp. 19–26, 2001. View at Publisher · View at Google Scholar
  17. N. Bhattacharyya, J. Tao, E. A. Klein, and S. Banerjee, “Alterations of transforming growth factor beta receptor II, insulin growth factor receptor II genes in microsatellite unstable prostate carcinomas,” Oncology Reports, vol. 11, no. 1, pp. 231–236, 2004. View at Google Scholar
  18. S. Takenoshita, A. Mogi, M. Tani et al., “Absence of mutations in the analysis of coding sequences of the entire transforming growth factor-ß type II receptor gene in sporadic human breast cancers,” Oncology Reports, vol. 5, no. 2, pp. 367–371, 1998. View at Google Scholar
  19. W. P. Schiemann, W. M. Pfeifer, E. Levi, M. E. Kadin, and H. F. Lodish, “A deletion in the gene for transforming growth factor β type I receptor abolishes growth regulation by transforming growth factor β in a cutaneous T-cell lymphoma,” Blood, vol. 94, no. 8, pp. 2854–2861, 1999. View at Google Scholar
  20. D. Wang, T. Kanuma, H. Mizunuma et al., “Analysis of specific gene mutations in the transforming growth factor-ß signal transduction pathway in human ovarian cancer,” Cancer Research, vol. 60, no. 16, pp. 4507–4512, 2000. View at Google Scholar
  21. T. Chen, J. Triplett, B. Dehner et al., “Transforming growth factor-ß receptor type I gene is frequently mutated in ovarian carcinomas,” Cancer Research, vol. 61, no. 12, pp. 4679–4682, 2001. View at Google Scholar
  22. M. Goggins, M. Shekher, K. Turnacioglu, C. J. Yeo, R. H. Hruban, and S. E. Kern, “Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas,” Cancer Research, vol. 58, no. 23, pp. 5329–5332, 1998. View at Google Scholar
  23. H. T. Zhang, Q. Y. Fei, F. Chen et al., “Mutational analysis of the transforming growth factor ß receptor type I gene in primary non-small cell lung cancer,” Lung Cancer, vol. 40, no. 3, pp. 281–287, 2003. View at Google Scholar
  24. T. Chen, C. Jackson, B. Costello et al., “An intronic variant of the TGFBR1 gene is associated with carcinomas of the kidney and bladder,” International Journal of Cancer, vol. 112, no. 3, pp. 420–425, 2004. View at Publisher · View at Google Scholar
  25. T. Chen, C. R. Jackson, A. Link et al., “Int7G24A variant of transforming growth factor-ß receptor type I is associated with invasive breast cancer,” Clinical Cancer Research, vol. 12, no. 2, pp. 392–397, 2006. View at Publisher · View at Google Scholar
  26. T. J. Knobloch, M. A. Lynch, H. Song et al., “Analysis of TGF-ß type I receptor for mutations and polymorphisms in head and neck cancers,” Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 479, no. 1-2, pp. 131–139, 2001. View at Publisher · View at Google Scholar
  27. T. Chen, W. Yan, R. G. Wells et al., “Novel inactivating mutations of transforming growth factor-ß type I receptor gene in head-and-neck cancer metastases,” International Journal of Cancer, vol. 93, no. 5, pp. 653–661, 2001. View at Publisher · View at Google Scholar
  28. J. Xu and L. Attisano, “Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor β signaling by targeting Smads to the ubiquitin-proteasome pathway,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 9, pp. 4820–4825, 2000. View at Publisher · View at Google Scholar
  29. M. Miyaki and T. Kuroki, “Role of Smad4 (DPC4) inactivation in human cancer,” Biochemical and Biophysical Research Communications, vol. 306, no. 4, pp. 799–804, 2003. View at Publisher · View at Google Scholar
  30. L. Garrigue-Antar, R. F. Souza, V. F. Vellucci, S. J. Meltzer, and M. Reiss, “Loss of transforming growth factor-β type II receptor gene expression in primary human esophageal cancer,” Laboratory Investigation, vol. 75, no. 2, pp. 263–272, 1996. View at Google Scholar
  31. H.-T. Zhang, X.-F. Chen, M.-H. Wang et al., “Defective expression of transforming growth factor ß receptor type II is associated with CpG methylated promoter in primary non-small cell lung cancer,” Clinical Cancer Research, vol. 10, no. 7, pp. 2359–2367, 2004. View at Publisher · View at Google Scholar
  32. S. H. Kang, Y. J. Bang, Y. H. Im et al., “Transcriptional repression of the transforming growth factor-ß type I receptor gene by DNA methylation results in the development of TGF-ß resistance in human gastric cancer,” Oncogene, vol. 18, no. 51, pp. 7280–7286, 1999. View at Publisher · View at Google Scholar
  33. M. Pinto, C. Oliveira, L. Cirnes et al., “Promoter methylation of TGFß receptor I and mutation of TGFß receptor II are frequent events in MSI sporadic gastric carcinomas,” Journal of Pathology, vol. 200, no. 1, pp. 32–38, 2003. View at Publisher · View at Google Scholar
  34. A. Báez, A. Cantor, S. Fonseca et al., “Differences in Smad4 expression in human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck squamous cell carcinoma,” Clinical Cancer Research, vol. 11, no. 9, pp. 3191–3197, 2005. View at Publisher · View at Google Scholar
  35. J. G. Herman, J. R. Graff, S. Myöhänen, B. D. Nelkin, and S. B. Baylin, “Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 18, pp. 9821–9826, 1996. View at Publisher · View at Google Scholar
  36. G. Chen, T. G. Gharib, C. C. Huang et al., “Discordant protein and mRNA expression in lung adenocarcinomas,” Molecular & Cellular Proteomics, vol. 1, no. 4, pp. 304–313, 2002. View at Google Scholar
  37. H. Osada, Y. Tatematsu, N. Sugito, Y. Horio, and T. Takahashi, “Histone modification in the TGFβRII gene promoter and its significance for responsiveness to HDAC inhibitor in lung cancer cell lines,” Molecular Carcinogenesis, vol. 44, no. 4, pp. 233–241, 2005. View at Publisher · View at Google Scholar
  38. B. Pasche, P. Kolachana, K. Nafa et al., “TßR-I(6A) is a candidate tumor susceptibility allele,” Cancer Research, vol. 59, no. 22, pp. 5678–5682, 1999. View at Google Scholar
  39. L. E. Pascal, L. D. True, D. S. Campbell et al., “Correlation of mRNA and protein levels: cell type-specific gene expression of cluster designation antigens in the prostate,” BMC Genomics, vol. 9, article 246, pp. 1–13, 2008. View at Google Scholar
  40. T. J. Moss and L. L. Wallrath, “Connections between epigenetic gene silencing and human disease,” Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 618, no. 1-2, pp. 163–174, 2007. View at Publisher · View at Google Scholar
  41. B. Pasche, T. J. Knobloch, Y. Bian et al., “Somatic acquisition and signaling of TGFBR1*6A in cancer,” The Journal of the American Medical Association, vol. 294, no. 13, pp. 1634–1646, 2005. View at Publisher · View at Google Scholar
  42. H.-T. Zhang, J. Zhao, S.-Y. Zheng, and X.-F. Chen, “Is TGFBR16A really associated with increased risk of cancer?” Journal of Clinical Oncology, vol. 23, no. 30, pp. 7743–7744, 2005. View at Publisher · View at Google Scholar
  43. Y. Bian, T. J. Knobloch, M. Sadim et al., “Somatic acquisition of TGFBR1*6A by epithelial and stromal cells during head and neck and colon cancer development,” Human Molecular Genetics, vol. 16, no. 24, pp. 3128–3135, 2007. View at Publisher · View at Google Scholar
  44. Y.-D. Mi, D. R. Borger, P. R. Fernandes, L. Pirisi, and K. E. Creek, “Loss of transforming growth factor-β (TGF-β) receptor type I mediates TGF-β resistance in human papillomavirus type 16-transformed human keratinocytes at late stages of in vitro progression,” Virology, vol. 270, no. 2, pp. 408–416, 2000. View at Publisher · View at Google Scholar
  45. C. J. Marsit, M. D. McClean, C. S. Furniss, and K. T. Kelsey, “Epigenetic inactivation of the SFRP genes is associated with drinking, smoking and HPV in head and neck squamous cell carcinoma,” International Journal of Cancer, vol. 119, no. 8, pp. 1761–1766, 2006. View at Publisher · View at Google Scholar
  46. J. Qi, Y.-Q. Zhu, J. Luo, and W.-H. Tao, “Hypermethylation and expression regulation of secreted frizzled-related protein genes in colorectal tumor,” World Journal of Gastroenterology, vol. 12, no. 44, pp. 7113–7117, 2006. View at Google Scholar
  47. T.-H. Liu, A. Raval, S.-S. Chen, J. J. Matkovic, J. C. Byrd, and C. Plass, “CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia,” Cancer Research, vol. 66, no. 2, pp. 653–658, 2006. View at Publisher · View at Google Scholar
  48. P. S. Yan, H. Shi, F. Rahmatpanah et al., “Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer,” Cancer Research, vol. 63, no. 19, pp. 6178–6186, 2003. View at Google Scholar